Does T790M disappear? Successful gefitinib rechallenge after T790M disappearance in a patient with EGFR-mutant non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 8, Issue 3, 2013, Pages

  Hata, Akito ^a   Katakami, Nobuyuki ^a   Kaji, Reiko ^a   Fujita, Shiro ^a   Imai, Yukihiro ^a  

^a INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN;

AGED; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CASE REPORT; DISEASE SEVERITY; EXON; GENETIC ANALYSIS; HUMAN; LETTER; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADENOCARCINOMA; DNA, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84874036499     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318282e047     Document Type: Letter

References (5)

1. Nakamura T, Sueoka-Aragane N, Iwanaga K, et al. Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA. J Thorac Oncol 2012;7: 1369-1381.
2. Chmielecki J, Foo J, Oxnard GR, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011;3: 90ra59.
3. O xnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011;17: 5530-5537.
4. O xnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011;17: 1616-1622.
5. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3: 75ra26.